May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Efficacy of Combined Treatment of Cyclosporine 0.05% and 1% Methylprednisolone on Dry Eye Patients of Sjogren Syndrome
Author Affiliations & Notes
  • Y. Byoun
    Yonsei University Medical College, Institute of Vision Research, Seoul, Republic of Korea
  • S. Kim
    Yonsei University Medical College, Institute of Vision Research, Seoul, Republic of Korea
  • T.-I. Kim
    Yonsei University Medical College, Institute of Vision Research, Seoul, Republic of Korea
  • E. Kim
    Yonsei University Medical College, Institute of Vision Research, Seoul, Republic of Korea
  • Footnotes
    Commercial Relationships Y. Byoun, None; S. Kim, None; T. Kim, None; E. Kim, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 401. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y. Byoun, S. Kim, T.-I. Kim, E. Kim; Efficacy of Combined Treatment of Cyclosporine 0.05% and 1% Methylprednisolone on Dry Eye Patients of Sjogren Syndrome. Invest. Ophthalmol. Vis. Sci. 2007;48(13):401.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To compare the efficacy of cyclosporine 0.05% (tCSA) and combined treatment with 1% methylprednisolone on treatment of keratoconjunctivitis sicca of Sjogren syndrome.

Methods:: 46 patients with moderate to severe dry eye diseases associated with Sjogren syndrome were treated with tCSA for 3 months. 20 subjects were treated with tCSA only and 26 subjects were treated with 1% methyl prednisolone and tCSA for initial 3 weeks, and treated with tCSA only thereafter. Corneal fluorescein staining, Schirmer score, tear break-up time (TBUT), and frequencies of artificial tear were evaluated before, 1month, and 3 months after treatment. Impression cytology of the bulbar conjunctiva was performed in 5 subjects at 3 months of treatment and compared to those of untreated patients with Sjogren syndrome.

Results:: After 1 month, combined treatment with 1% methyl prednisolone significantly improved corneal fluorescein score (p=0.04) and mean schirmer score (p=0.04), whereas solitary use of tCSA resulted in improvement of corneal fluorescein score (p=0.02) only . However, after 3 month, significant improvements were observed in corneal fluorescein staining score (combined, solitary: p<0.01, p=0.03), TBUT (p<0.01, p=0.03), mean schirmer score (p<0.01, p=0.04) and frequencies of artificial tear use (p<0.01, p=0.04) in both groups, and there was no statistical difference between two treatment modalities. In impression cytology, significant increase of periodic acid-Schiff positive cells compared to untreated patients was observed.

Conclusions:: Treatment with tCSA appears to be safe and effective in KCS patients with Sjogren syndrome. Combined use of 1% methyl prednisolone improved clinical scores in short periods, however this differences did not persist up to 3 months.

Keywords: cornea: tears/tear film/dry eye • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×